Altimmune $ALT Read from its own SEC filings · nothing written, nothing inferred
🫧 Edgar looked up ALTIMMUNE, INC. ($ALT). Last filing: 8-K (5.02 Departure or Election of Directors; Appointment of Officers), 2026-09-29. 15 event filings (8-K) in the past twelve months.
🔖 Exposure: revenue $41K (FY2025), total debt $34.3M. Experience: revenue up 105.0% on the year, down 68.9% a year over 4 years; operating margin -230461.0%, up from -515860.0%. Soundness: equity 80.3% of assets, return on equity -39.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $36K and $64K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -230461.0% against a -3.8% median; growth 105.0% against 13.7%.
Cash
| Cash flow (op · inv · fin · free) | −$68M · −$132M · $207M · −$68M |
| Investment book (cash · short · long) | $44M · $230M · — · current ratio 18.55 |
The figures, as filed
| Fiscal year end | 2025-12-31 |
| Revenue | $0M |
| Revenue, on the year | 105.0% |
| Revenue, a year over the record | −68.9% |
| Operating margin | −230461.0% |
| Operating margin, prior year | −515860.0% |
| Net margin | −214861.0% |
| Research and development | $66M · 162029.3% of revenue |
| Total debt | $34M |
| Equity of assets | 80.3% |
| Return on equity | −39.2% |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $-1 |
| Book value per share | $2.55 |
| Revenue per share | $0.00 |
| Shares outstanding | 88,104,132 |
| Audited years read | 5 |
Peers: the median of 114 filers with $50M+ revenue in pharmaceutical preparations.
Health HarborAltimmune sails as: Weathered boat
Health watch · 12 monthsDirector or officer change ×3
No growth figure to set the speed.
🌊 Visit the Bay →- operating cash flow was negative (-$67.5M in FY2025)
- revenue is hard to predict: its 80% range is ±28%
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
- 8-K · 2026-09-29 · 5.02 Departure or Election of Directors; Appointment of Officers
- 10-Q · 2026-08-12
- 8-K · 2026-08-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits
- 8-K · 2026-07-28 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits
- 8-K · 2026-06-16 · 8.01 Other Events
- 10-Q · 2026-05-13
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company